SGI-1776
SGI-1776 Basic information
- Product Name:
- SGI-1776
- Synonyms:
-
- N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine
- N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine SGI-1776
- SGI-1776
- SGI-1776 free base
- N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine
- SGI-1776, >=98%
- SGI-1776 free base N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine
- SGI-1776 FREE BASE;SGI1776
- CAS:
- 1025065-69-3
- MF:
- C20H22F3N5O
- MW:
- 405.42
- EINECS:
- 200-258-5
- Product Categories:
-
- Inhibitors
- JAK
- Inhibitor
- JAK/STAT
- STAT
- Mol File:
- 1025065-69-3.mol
SGI-1776 Chemical Properties
- Density
- 1.37
- storage temp.
- Store at -20°C
- solubility
- ≥40.5 mg/mL in DMSO; insoluble in H2O; ≥101 mg/mL in EtOH
- pka
- 9.22±0.10(Predicted)
- form
- Solid
- color
- White to yellow
SGI-1776 Usage And Synthesis
Uses
A novel, ATP competitive inhibitor of Pim1, Pim2 and Pim3 with IC50s of 7 nM, 363 nM and 69 nM, respectively.
Uses
SGI-1776 is a Pim-1 kinase inhibitor. Potent PIM inhibitor.
Definition
ChEBI: N-[(1-methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-6-imidazo[1,2-b]pyridazinamine is a member of imidazoles.
Biological Activity
sgi-1776 free base, n-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine, is a potent atp-competitive inhibitor of the serine/threonine family of pim kinase, an enzyme regulating cell survival. through extensive biomedical characterization, sgi-1776 exhibits specificity to the three isoforms of the pim family, including pim-1, pim-2, and pim-3. according to preliminary results from studies treating prostate cancer cells, sgi-1776 dose-dependently reduces phosphorylation of known pim kinase substrates involved in cell cycle progression and apotosis (p21cip1/waf1 and bad), compromises overall cell viability by inducing g1 cell cycle arrest and triggering apoptosis, and reduces cell viability in a multidrug resistance 1 (mdr1) protein based taxane-refractory prostate cancer cell line.shannon m. mumenthaler, patricia y.b. ng, amanda hodge, davide bearss, gregory berk, sarath kanekal, sanjeev redkar, pietro taverna, davide b. agus, and anjali jain. pharmacological inhibition of pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. mol cancer ther. 2009; 8(10): 2882-2893lisa s. chen, s anjeev redkar, david bearss, william g. wierda and varsha gandhi. pim kinase inhibitor, sgi-1776, induces apoptosis in cll lymphocytes. blood. 2009; 114(19): 4150-4157
target
Pim1
SGI-1776Supplier
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- +86 (531) 88811783
- sales@trio-pharmatech.com (International market)
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 86-21-34053660
- sale@labgogo.com